Read more
Silviu Itescu's photo - Managing Director & CEO of Mesoblast

Managing Director & CEO

Silviu Itescu

CEO Approval Rating





PublicIndependent CompanyAustralian Securities ExchangeMSB

Mesoblast Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue


Mesoblast's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 28M. Over the last four quarters, Mesoblast's revenue has grown by 52.9%. Specifically, in Q2 2021's revenue was $2M; in Q1 2021, it was $1.9M; in Q4 2020, it was $2.2M; in Q3 2020, Mesoblast's revenue was $1.3M.

Mesoblast News

Mesoblast Press Releases

Social Media

Mesoblast Headquarters

55 Collins Street Level 38

Melbourne, Victoria3000


Driving Directions »

Mesoblast Summary



Mesoblast is a Victoria-based regenerative medicine company that develops therapeutics for the treatment of inflammatory and cardiovascular diseases. Mesoblast was founded in 2004. Mesoblast's headquarters is located in Melbourne, Victoria, AU 3000. I...


Mesoblast's Managing Director & CEO, Silviu Itescu, currently has an approval rating of 89%. Mesoblast's primary competitors are Athersys, Pluristem & Cynata.


Recent investment data cannot be found related to Mesoblast

Frequently Asked Questions about Mesoblast

  1. When was Mesoblast founded?

    Mesoblast was founded in 2004
  2. Who is Mesoblast's CEO?

    Mesoblast's CEO is Silviu Itescu
  3. How much revenue does Mesoblast generate?

    Mesoblast generates $7.5M in revenue
  4. How much funding does Mesoblast have?

    Mesoblast has historically raised $567.4M in funding
  1. Where is Mesoblast's headquarters?

    Mesoblast's headquarters is in Melbourne Victoria, AU
  2. How many employees does Mesoblast have?

    Mesoblast has 83 employees
  3. What sector does Mesoblast operate in?

    Mesoblast is in Pharmaceuticals
  4. Who are Mesoblast's competitors?

    Mesoblast's top competitors are Athersys, Pluristem, Cynata

Trending Companies